We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising
33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we …

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic
annotation data along with multi-platform molecular profiles of more than 11,000 human tumors …

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-…

Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced
algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on …

We conducted comprehensive integrative molecular analyses of the complete set of tumors
in The Cancer Genome Atlas (TCGA), consisting of approximately 10,000 specimens and …

Cancer progression involves the gradual loss of a differentiated phenotype and acquisition
of progenitor and stem-cell-like features. Here, we provide novel stemness indices for …

DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic
response. We systematically analyzed somatic alterations to provide a comprehensive view of …

Cancer develops through a process of somatic evolution 1 , 2 . Sequencing data from a single
biopsy represent a snapshot of this process that can reveal the timing of specific genomic …

Aneuploidy, whole chromosome or chromosome arm imbalance, is a near-universal
characteristic of human cancers. In 10,522 cancer genomes from The Cancer Genome Atlas, …

Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers
with different genetic drivers, clinical courses, and therapeutic responses. The current …